Amedisys U.S. Settlement Left Some Concerns Unresolved, Shows Flexibility on Remedies
August 14, 2025
By: Ilana Kowarski and Flavia Fortes
MLex
Axinn managing partner Jeny Maier was quoted in the MLex article, "Amedisys U.S. Settlement Left Some Concerns Unresolved, Shows Flexibility on Remedies."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Consero Healthcare General Counsel Forum 2025
Speaking Engagement
Antitrust
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Pro Bono Partnership 28th Anniversary Gala
Sponsorship
Antitrust
Ronald McDonald House New York Together in Gold Annual Gala
Sponsorship
Antitrust
How Justices' Ruling Upends Personal Jurisdiction Defense
Byline Articles
Litigation & Trials